Amgen’s $3.7bn ChemoCentryx Buy May Help Offset Growing Pains
Big Biotech’s Q2 Revenue Was 1% Above Consensus
Amgen is acquiring a pipeline-in-a-pill with ChemoCentryx’s Tavneos, currently approved for ANCA-associated vasculitis, at a time when the company’s existing portfolio is struggling to maintain sales growth.
